TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.
About TherVacB
For Patients
TherVacB Team
Partners
European countries
Project duration (months)
Let’s Talk About Ethics in Clinical Research – A FREE Session on Privacy Concerns in Social Media Patient Recruitment, 24.11.2022
An online lecture explores ethical benefits and challenges of social media recruitment for clinical studies. Recruiting patients for clinical studies through social media yields ethical benefits and challenges. On 24th November 2022 at 15:00 CET, TherVacB experts in...
Happy World Hepatitis Day 2022!
Globally, 325 million people live with hepatitis, one of the most neglected diseases. On World Hepatitis Day 2022, the TherVacB project coordinator, Prof. Ulrike Protzer, joins the collective voices from across the world to raise awareness about Hepatitis B (HBV) and...
European Testing Week, 22-29 November 2021
Get your one-off screening for hepatitis B from your GP in Germany Hepatitis B can be treated well at an early stage, hepatitis C can even be cured. In Germany, like in other countries and regions of the world, many people affected are unaware of their infection....
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
TherVacB Publications
Find here scientific publications and technical articles from TherVacB project partners.
Read more about chronic hepatitis B, the virus, screening and testing for hepatitis C and B, therapeutic vaccination, and cure research.
All you need to know to understand Hepatitis B cure research – The HBV Cure FAQs
Watch the growing collection of short videos answering key questions on cure research raised by people living with Hepatitis B (HBV). The collection is a product of an international consortium of organizations, expert institutions and research projects working in and around Hepatitis B. Actively involved are ICE-HBV, Hepatitis B Foundation, World Hepatitis Alliance, HepBCommunity.org, Australian Centre for Hepatitis Virology, IP-cure-B, the Canadian HBV Network and TherVacB.
⏰We are just starting, you are welcome to join in:
https://cutt.ly/TherVacB-Lecture_Register
📲💻
📢It's today at 3⃣- 4⃣ PM CET!
💡Let's talk about #ethics of #socialmedia #patientrecruitment in #clinicaltrials
🖊️Get the event link here: https://cutt.ly/TherVacB-Lecture_Register
@TherVacB_EU @TU_Muenchen @bettizimm @TheresaWillem #digitalhealth @EU_Health https://twitter.com/TheresaWillem/status/1595074836677672961
⏰Free at 3 PM CET today?
Working in #clinicaltrials design or coorindation? Are you recruiting #patients and want to use #socialmedia?
Join us to discuss and learn more from #bioethicists @bettizimm and @TheresaWillem
➡️https://cutt.ly/TherVacB-Lecture_Register
Do you wonder how to #recruit patients for your #clinical study via #socialmedia?
Join the expert session with @TheresaWillem and @bettizimm to learn more about benefits, #ethical considerations, red flags.
➡️Register here: https://cutt.ly/TherVacB-Lecture_Register
@EU_Health #digitalhealth https://twitter.com/TherVacB_EU/status/1585571914831089664
Addressing viral hepatitis B, D and C to reduce the incidence of #livercancer should be considered in all the cancer prevention initiatives mentioned in the Europe Beating Cancer Plan @EuroTestWeek #EuroTestWeek #TestTreatPrevent @EU_Health @WHO_Europe @hans_kluge @SKyriakidesEU
Young investigators in #hepatology and #liver research, don't miss tomorrow's webinar on designing clinical studies, at 17:00 CET💡
Learn from experts @JuanAbraldes, @ruben_hernaez &
@MajaThiele🤗
ℹ
@MattiasMandorf1 @SaborowskiAnna @MartaBAfonso
YI Afterwork Series: Live(r) webinar on designing clinical studies - EASL-The Home of Hepatology.
This edition of the YI Afterwork Series Live(r) webinar aims to facilitate the conduct of clinical studies.
easl.eu